A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/26021

Title:	A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma.
Authors:	Anderson, Peter M Bielack, Stefan S Gorlick, Richard G Skubitz, Keith Daw, Najat C Herzog, Cynthia E Monge, Odd R Lassaletta, Alvaro Boldrini, Erica Pápai, Zsuzanna Rubino, Joseph Pathiraja, Kumudu Hille, Darcy A Ayers, Mark Yao, Siu-Long Nebozhyn, Michael Lu, Brian Mauro, David View more
Keywords:	Ewing sarcoma antibody therapy of cancer bone sarcoma osteosarcoma resistance tumor growth factor View more
Mesh:	Adolescent Adult Aged Antibodies, Monoclonal Bone Neoplasms Child Female Humans Ki-67 Antigen Male Middle Aged Osteosarcoma Receptor, IGF Type 1 Sarcoma, Ewing View more
Issue Date:	2016
Citation:	Pediatr Blood Cancer.2016 10;(63)10:1761-70
Abstract:	Robatumumab (19D12; MK-7454 otherwise known as SCH717454) is a fully human antibody that binds to and inhibits insulin-like growth factor receptor-1 (IGF-1R). This multiinstitutional study (P04720) determined the safety and clinical efficacy of robatumumab in three separate patient groups with resectable osteosarcoma metastases (Group 1), unresectable osteosarcoma metastases (Group 2), and Ewing sarcoma metastases (Group 3).
PMID:	27362300
URI:	https://hdl.handle.net/20.500.12530/26021
Rights:	openAccess
Appears in Collections:	Fundaciones e Institutos de Investigación > FIB H. Infantil U. Niño Jesús > Artículos

Files in This Item:

File	Description	Size	Format
PMC5129487.pdf		272.92 kB	Adobe PDF	View/Open